Allied Minds PLC Precision Biopsy appoints Chief Operating Officer
11 July 2018 - 4:00PM
RNS Non-Regulatory
TIDMALM
Allied Minds PLC
11 July 2018
Allied Minds subsidiary Precision Biopsy appoints Adam Savakus
as Chief Operating Officer
Boston, MA (11 July 2018) - Allied Minds subsidiary, Precision
Biopsy, today announces the appointment of Adam Savakus as Chief
Operating Officer.
This appointment represents an important investment in Precision
Biopsy's regulatory and clinical expertise at a key juncture in its
development as its lead diagnostic product, ClariCore(TM) , enters
a pivotal Cohort B study.
Adam is an accomplished medical device executive with direct
experience driving successful operational, regulatory and marketing
outcomes. Most recently as Executive Vice President at Relievant
MedSystems, he was responsible for clinical and regulatory strategy
design and execution for the Intracept device targeted at relief of
chronic lower back pain. As with Precision Biopsy's ClariCore
product, Intracept under Adam's leadership secured a 510(k)
approval pathway and was ultimately approved by the FDA in July
2016. Prior to Relievant, Adam served as Vice President, Cinical
and Regulatory Affairs at Adiana Inc (later Cytyc), and as Vice
President, Clinical and Regulatory Affairs and Quality Assurance at
EndoSonics. Adam holds a B.S. in Biophysics and a B.S.
Bioengineering, both from The Pennsylvania State University.
Jill Smith, CEO of Allied Minds commented "We are delighted to
make this investment in additional talent at Precision Biopsy. We
believe Adam's direct experience in leading successful FDA
outcomes, as well as in marketing and quality control, will be
invaluable to the Precision Biopsy team."
Amir Tehrani, CEO of Precision Biopsy, commented "We warmly
welcome Adam to the team and look forward to leveraging his highly
relevant experience and skill set during this next exciting phase
for our company."
Adam Savakus commented "I am excited to be joining the Precision
Biopsy team given the promising clinical trial results to date and
I look forward to bringing my experience and contacts to bear as
ClariCore enters its pivotal Cohort B study."
ENDS
For more information, please contact:
Allied Minds plc +44 7771 872 922
Neil Pizey, Head of Corporate IR@alliedminds.com
Development
FTI Consulting
Ben Atwell / Brett Pollard +44 20 3727 1000
About Allied Minds
Allied Minds plc is an IP commercialisation company focused on
early stage company creation and development within the technology
and life science sectors. With origination relationships spanning
US federal laboratories, universities, and leading US corporations,
Allied Minds sources, operates and funds a portfolio of companies
to generate long-term value for its investors and stakeholders.
Based in Boston, Allied Minds supports its businesses with capital,
management, expertise and shared services.
Allied Minds Forward-Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to
Allied Minds' future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in Allied Minds' regulatory filings. These forward-looking
statements are based on assumptions regarding the present and
future business strategies of Allied Minds and the environment in
which it will operate in the future. Each forward-looking statement
speaks only as at the date of this press release. Except as
required by law, regulatory requirement, the Listing Rules and the
Disclosure Guidance and Transparency Rules, neither Allied Minds
nor any other party intends to update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAURSARWWABAUR
(END) Dow Jones Newswires
July 11, 2018 02:00 ET (06:00 GMT)
Allied Minds (LSE:ALM)
Historical Stock Chart
From Apr 2024 to May 2024
Allied Minds (LSE:ALM)
Historical Stock Chart
From May 2023 to May 2024